Loading patent…
AssigneeEcole Polytechnique Federale de Lausanne
InventorsAlexandre Marti, Norbert Lange, Mattieu Zellweger, Georges Wagnieres, Hubert Van Dew Bergh, Patrice Jichlinski, Pavel Kucera
Estimating the term…
The invention concerns a 5-aminolevulinic acid ester (E-ALA) solution for producing a pharmaceutical preparation useful for diagnosing and/or treating tissue and/or cell pathologies by local radiation exposure using radiation emitted by a light source energy followed, in the case diagnosis, by detection of fluorescent protoporphyrin IX (Pp1X). The E-ALA concentration in the solution is less than 1% and ranges between 0.01% and 0.5%. The low E-ALA concentration in the solution increases Pp1X synthesis and homogenises its distribution in the cell layers while highly reducing the secondary toxicity for the treated cells.
A 5-aminolevulinic acid ester (E-ALA) solution for producing a pharmaceutical preparation used in the diagnosis and/or treatment of tissue and/or cell lesions with local irradiation using a beam emitted by a source of light energy, which is followed, in the case of diagnosis, by detecting the fluorescence emitted by substances to which 5-aminolevulinic (ALA) or E-ALA acids are precursors, particularly protoporphyrin IX (Pp1X), characterized in that the concentration C of ALA (E-ALA) ester in the solution is lower than 1% and ranges from 0.01% to 0.5%.
Dependencies are inferred from the claim text.